Trials Closed to Recruitment Trails

AIM HIGH - Principal Investigator: Dr. Geoffrey Douglas

To assess the effects of  the addition of  slow release Niacin to clinical outcomes in Coronary Artery disease therapy

dal PLAQUE II - Principal Investigator: Dr. Robert Teskey

Measuring the effect of dalcetrapib (investigational drug that raises HDL) on Atherosclerotic Disease as measured by intravascular ultrasound (IVUS) and carotid ultrasound.

PANORAMIC - Principal Investigator: Dr. Satish Toal

The purpose of the study is to look at the possible effect of the St Jude Medical vibrating Patient Notifier™ feature of an implantable cardioverter defibrillator (ICD) on a patient's level of anxiety. 

PROTECTION AMI   - Principal Investigator: Dr. Colin Barry

The purpose of this study is to learn if different doses of investigational drug called KAI-9803 is safe and can help to prevent damage to the heart when given before and during the PCI procedure for a heart attack.

RAFT - Principal Investigator: Dr. Satish Toal

The purpose of this study is to determine whether a therapy called Cardiac Resynchronization Therapy (CRT) combined with an Implantable Cardioverter Defibrillator (ICD) will improve survival and reduce the number of hospitalizations for heart failure patients.

SATURN - Principal Investigator: Dr. Robert Teskey

The purpose of this study is to compare the effects of either 40 mg of rosuvastatin or 80 mg of atorvastatin, taken daily for two years, on the progression of coronary artery disease, and to determine if these drugs will reduce the fatty deposits (atheroma) in a patient's arteries.

TIMI 50 - Principal Investigator: Dr. Vernon Paddock

The purpose of the study is to test the safety and effectiveness of SCH 530348 (an investigational medication), when used with standard medications for treatment of atherosclerosis.

TRA*CER - Principal Investigator: Dr. Sohrab Lutchmedial

The purpose of this study is to determine whether SCH 530348 when added to standard of care treatment works better than the present available therapy alone, clopidogrel (PlavixÒ) at lowering deaths, future heart attacks or strokes.  As well, the study will determine the safety of SCH 530348 and any side effects that might be associated with this drug.